Anchor Therapeutics Achieves Milestone in GPCR Collaboration
Significant Progress Over First Four Months of Joint Research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 7, 2011 - Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI). This achievement represents rapid progress for the collaboration, which was launched in September 2010 to develop G protein coupled receptor (GPCR)–targeted therapeutic compounds utilizing Anchor's proprietary pepducin technology.
Under the agreement, Anchor and OMJPI work jointly to discover and optimize preclinical development candidates against GPCR targets in oncology and metabolic disorders. During this initial research phase, Anchor pepducins were shown to have in vivo efficacy in a relevant model and satisfactorily achieved other criteria necessary to earn further research funding support. These results triggered an undisclosed cash payment to Anchor.
“The rapid progress in this collaboration demonstrates Anchor's ability to discover promising new pepducin therapeutic compounds. Our work together with OMJPI has been extremely efficient and cooperative,” said Frederick Jones, M.D., President and CEO of Anchor.
About Pepducin Technology
Pepducins are lipidated peptides designed to be allosteric modulators for G protein coupled receptor (GPCR) targets, especially those intractable to current approaches. They are composed of a short peptide derived from a GPCR intracellular loop linked to a lipid moiety. This structure allows pepducins to anchor in the cell membrane and target the GPCR protein via a unique intracellular allosteric mechanism. The pepducin technology platform represents an entirely new paradigm for modulating GPCR signal transduction, potentially transforming the scope of GPCR therapeutics to treat a much wider range of serious illnesses including inflammatory and metabolic diseases. Pepducin technology is licensed exclusively to Anchor Therapeutics.
About Anchor Therapeutics
Anchor Therapeutics designs and develops peptide modulators of G protein coupled receptors (GPCRs), the largest family of drug targets. Anchor's peptides, called pepducins, modulate GPCR activity utilizing a unique intracellular allosteric mechanism that is well suited for a wide variety of targets, including intractable and orphan receptors. Anchor and its pharma collaborators are leveraging the broad applications of pepducin technology to create new treatment options for regenerative medicine, diabetes, inflammation and cancer. For more information please visit www.anchortx.com.
Contact: Anchor Therapeutics
Frederick Jones, M.D., 617-715-1999
MacDougall Biomedical Communications
Jacqui Miller, 781-235-3060
Posted: January 2011